Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS ANNOUNCES APPOINTMENT OF DAVID SWETLOW AS CHIEF FINANCIAL OFFICER

Ventripoint Diagnostics Ltd. has appointed David Swetlow, CPA, CA, iGP, as chief financial officer, effective immediately.

This appointment represents an important step in strengthening Ventripoint's leadership team as the company embarks on its new commercial strategic vision and transitions into its growth phase.

Mr. Swetlow brings extensive senior management, financial and public company leadership experience from various roles across high-growth medical technology and innovative life science companies, including Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT and Xillix, with a record of building and executing robust capital markets strategies; company scale-up, product launch and commercialization strategies success; driving and evolving financial systems, reporting and operational performance for next-stage growth; strategic relationship management; and enhancing corporate governance. His broad expertise will be instrumental to positioning Ventripoint to achieve the next stage of VMS+ platform market adoption success and expansion abroad.

"This is a pivotal moment for Ventripoint," said Hugh MacNaught, president and chief executive officer of Ventripoint Diagnostics. "David's leadership will play a vital role as we execute on a refreshed commercial strategy designed to scale our technology and platform, strengthen our global partnerships, and position the company for new markets and revenue growth.

As Ventripoint moves into this next stage, the company also extends its appreciation to Jimmy Jeon, who has resigned as CFO, and Marelli Services for their valuable support to date. Their contributions have helped provide stability and continuity through a period of important transition.

As CFO, Mr. Swetlow will oversee financial strategy, capital markets, financial reporting and operations, working closely with the executive team and board of directors as Ventripoint advances commercialization efforts in the United States, Canada, Europe, the United Kingdom and other priority markets.

"The VMS+ technology platform stands at the forefront of cardiac imaging innovation, harnessing and leveraging the convergence of AI with imaging diagnostics to enable what hasn't previously been readily accomplishable cost-effectively in the health care ecosystem, nor in a near to real-time manner to enhance care and reduce the anxious wait times for at-risk cardiac patients to find out further answers," said Mr. Swetlow. "I am excited to join Ventripoint at this critical juncture to evolve the financial and commercial foundations needed to scale and make this technology globally available for current and expanded indications."

This appointment represents another foundational step in building a high performance leadership team capable of guiding Ventripoint through its scale up phase. With a renewed commercial focus and a rapidly growing global interest in the company's VMS+ cardiac imaging solution, the addition of an experienced public company life sciences industry CFO strengthens Ventripoint's ability to deliver on its strategic priorities and realize on opportunities ahead.

The board of directors has awarded Mr. Swetlow one million options, exercisable at 11 cents, with a term of 10 years and vesting over 12 months.

In other news, the company wishes to correct the news release of Sept. 3, 2025, as the insider reported to have invested $105,000 has been determined not to be an insider of the company.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

We seek Safe Harbor.